Lisata Therapeutics amends merger agreement with Kuva Labs, setting $4.00 per share price plus CVRs
Lisata Therapeutics and Kuva Labs amended their merger agreement dated March 6, 2026, revising the offer price to $4.00 per share in cash plus one contingent value right (CVR) per share for future milestone payments. The amendment extends the offer commencement timeline and modif
View filing at SEC.gov →